Aurinia Pharmaceuticals (AUPH) Earnings Date, Estimates & Call Transcripts $8.21 +0.01 (+0.12%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$8.18 -0.03 (-0.41%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aurinia Pharmaceuticals Earnings Summary Latest Q2 Earnings DateAug. 1EstimatedConsensus EPS (Aug. 1) $0.01 Actual EPS (Aug. 1) $0.01 Actual Revenue (Aug. 1) $57.10MAurinia Pharmaceuticals posted Q2 2024 earnings on August 1, 2024, reporting an EPS of $0.01, which met analysts' consensus estimates of $0.01. Quarterly revenue rose 37.6% year-over-year to $57.10 million, above analyst estimates of $54.25 million. With a trailing EPS of $0.05, Aurinia Pharmaceuticals' earnings are expected to grow 409.09% next year, from $0.11 to $0.56 per share. Q2 2024 Earnings ResourcesQ2 2024 Earnings ReportConference Call Transcript & Audio Quarterly Report (10-Q) Press Release (8-K)SEC FilingPowered by Get Aurinia Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aurinia Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAUPH Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AUPH Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Aurinia Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20251$0.10$0.10$0.10Q2 20251$0.04$0.04$0.04Q3 20251$0.04$0.04$0.04Q4 20251$0.05$0.05$0.05 Aurinia Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/1/2024Q2 2024$0.01$0.01-$0.03$54.25M$57.10M5/2/2024Q1 2024-$0.17-$0.03+$0.14$0.01$46.30M$50.30M2/15/2024Q4 2023-$0.16-$0.19 -$0.03-$0.19$45.00M$45.10M11/2/2023Q3 2023-$0.17-$0.09+$0.08-$0.09$38.41M$54.52M8/3/2023Q2 2023-$0.20-$0.08+$0.12-$0.08$37.90M$41.49M Aurinia Pharmaceuticals Earnings - Frequently Asked Questions When did Aurinia Pharmaceuticals announce their last quarterly earnings? Aurinia Pharmaceuticals (NASDAQ:AUPH) last announced its quarterly earning data on Thursday, August 1, 2024. Learn more on AUPH's earnings history. What guidance has Aurinia Pharmaceuticals issued on next quarter's earnings? Aurinia Pharmaceuticals updated its FY 2025 earnings guidance on Thursday, February, 27th. The company issued revenue guidance of $250.0 million-$260.0 million, compared to the consensus revenue estimate of $274.4 million. Did Aurinia Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Aurinia Pharmaceuticals (NASDAQ:AUPH) reported $0.01 earnings per share (EPS) to hit the analysts' consensus estimate of $0.01. Learn more on analysts' earnings estimate vs. AUPH's actual earnings. How can I listen to Aurinia Pharmaceuticals's earnings conference call? The conference call for Aurinia Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Aurinia Pharmaceuticals's conference call transcript? The conference call transcript for Aurinia Pharmaceuticals's latest earnings report can be read online. Read Transcript How can I view Aurinia Pharmaceuticals's earnings report? Aurinia Pharmaceuticals's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Aurinia Pharmaceuticals generate each year? Aurinia Pharmaceuticals (NASDAQ:AUPH) has a recorded annual revenue of $235.13 million. How much profit does Aurinia Pharmaceuticals generate each year? Aurinia Pharmaceuticals (NASDAQ:AUPH) has a recorded net income of -$78.02 million. AUPH has generated $0.05 earnings per share over the last four quarters. What is Aurinia Pharmaceuticals's EPS forecast for next year? Aurinia Pharmaceuticals's earnings are expected to grow from $0.11 per share to $0.56 per share in the next year, which is a 409.09% increase. More Earnings Resources from MarketBeat Related Companies PCVX Earnings Results RYTM Earnings Results PTCT Earnings Results RNA Earnings Results ZLAB Earnings Results RARE Earnings Results ACLX Earnings Results SWTX Earnings Results AKRO Earnings Results OGN Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback PlanMicrosoft Crushes Earnings, What’s Next for MSFT Stock?Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay AwayAMD Stock Signals Strong Buy Ahead of Earnings This page (NASDAQ:AUPH) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AUPH Stock Free AUPH Stock Alerts